185 results about "BACTERIAL INFECTIOUS DISEASES" patented technology

The invention discloses the components and preparation method of beta-lactam injection. The beta-lactam injection comprises 5 to 20 percent of beta-lactam antibiotics, 0.05 to 5 percent of suspending agent, 0.005 to 0.3 percent of antioxygen, 0.1 to 0.2 percent of nonionic surfactant and the balance of vegetable oil or grease for injection. The injection can be used for preventing and curing animal bacterial infectious diseases and can be injected hypodermically or in muscle and be applied through breast for a few times. The preparation method provided by the invention comprises: firstly, making the antibiotics and the antioxygen into micro powder and making the suspending agent into fine powder; secondly, adding the vegetable oil or grease for injection, which is sterilized at high temperature, into the fine powder of the suspending agent, heating the mixture, uniformly mixing the mixture and keeping the mixture in a sterile environment to cool the mixture to room temperature for later use; and finally, transferring the prepared oil or grease added with the suspending agent to a colloid mill, adding medicament micro powder, the antioxygen and the non-ionic surfactant with stirring, and performing uniform mixing and sterilization to obtain the beta-lactam injection.

This invention provides compounds of formula (I) or its pharmacologically acceptable salt or solvate, wherein A represents aryl or a monocyclic or bicyclic heterocyclic group, R1 represents a halide, nitro, substituted C1-6 alkyl, optionally substituted amino, C1-6 alkyloxycarbonyl, optionally substituted aryl, a heterocyclic group, or heterocyclic carbonyl, R2 represents a hydrogen atom or C1-6 alkyl, R3 represents C1-6 alkyl, all of R4, R5, and R6 represent a hydrogen atom, R7 represents C1-6 alkyl, m is 1 or 2, and n is 1. The compounds are novel lincomycin derivatives having a potent activity against resistant pneumococci. The compounds can be used as an antimicrobial agent and are useful for preventing or treating bacterial infectious diseases.

The present invention relates to preparation of a blattodea polypeptide, and uses of the blattodea polypeptide in anti-gram-positive bacteria and anti-gram-negative bacteria. Specifically the present invention relates to a blattodea extract effective fraction having a function of prevention and treatment of bacterial infection diseases, a preparation method and a medical use thereof. The Periplaneta Americana extract effective fraction of the present invention is a polypeptide substance with a molecular weight less than 5000 dalton, and is prepared by the following steps: carrying out solvent extraction and membrane separation on fresh polypide or dried polypide of Periplaneta Americana to obtain the product of the present invention, wherein the polypeptide active substance of the effective fraction has significant anti-gram-positive bacteria activity and anti-gram-negative bacteria activity, can be prepared into forms of a hydrogel, a cataplasm, lyophilized powder, a water agent, an aerosol, a suppository, a film agent, an external application liniment, and an ointment, and can be used for preparations of drugs for prevention and treatment of diseases related to gram-positive bacteria and gram-negative bacteria and infections, daily chemical products or medical devices.

The present invention discloses a compound scutellaria injection for curing infectious diseases in livestock and poultry, characterized in that the injection is prepared from the following raw materials with the weight portions: 10 to 50 portions of scutellaria, 30 to 100 portions of radix bupleuri, 30 to 100 portions of honeysuckle, 30 to 100 portions of cordate houttuynia, 30 to 100 portions of dyers woad root, 30 to 100 portions of Daqing leaf, 10 to 15 portions of tween 80 and 10 to 15 of benzyl alcohol; and the water for injection is appropriately confected to 1,000. The present invention is a pure Chinese medicine injection with quick effect, high curing effect, rare recurrence after cure and no drug resistance of bacteria. The present invention with no side effect on livestock and poultry and safe use has the curing rate of virus and bacterial infectious diseases in poultry up to 95 percent and of toxic epidemic diseases and bacterial diseases in other livestock up to 82 percent.

The inventors have developed conductive formulations and methods of use thereof containing conductive agents that are ionic or readily ionizable in aqueous or organic solvent environments, such as salts, ionic surfactants, or other substances. The formulation may optionally contain one or more active agents, eg, antiviral, antimicrobial, anti-inflammatory proteins or peptides. The active agent can be co-administered or incorporated into the formulation, or can be administered after administration of the conductive formulation. When applied to a mucosal lining fluid, the formulation alters the physical properties of the mucosal lining, such as surface tension, surface elasticity, and bulk viscosity. The formulations are administered in amounts sufficient to alter the biophysical properties of the mucosal lining in vivo. The formulation can be administered for several different purposes: to reduce the spread of viral and bacterial infectious diseases such as SARS, influenza, tuberculosis, and RSV in humans, and foot-and-mouth disease in artiodactyls; Ambient pollution caused by particle formation when sneezing or talking is particularly important in the use of clean rooms; reducing or preventing the occurrence of obstructive sleep apnea and some cases of irritable bowel syndrome; and controlling the intake of drug molecules and pathogens into the dynamics.

The invention provides a preparation to prevent and cure endometritis of milch cow. It comprises soluble staphylococcus enzyme, Lysozyme, bacteriostatic peptide and carrier. It has strong sterilizing effect, wide sterilizing spectrum and strong stability, easy to accept by human body. The curative effect is quick and it is convenient to use. It can be applied to prevent and cure not only endometritis of milch cow, but also bacterial infectious diseases of milch cow or other animals such as acute and chronic mastitis, colpitis, foot&mouth disease, stomatitis, etc.

The invention relates to the field of microorganisms, and specifically provides a novel staphylophage and a composition, as well as preparation methods and application thereof. The phage is aureus staphylophage J1P1 with the storage number of CCTCC NO: M2016284, aureus staphylophage J1P2 with the storage of CCTCC NO: M2016285, aureus staphylophage J1P3 with the storage of CCTCC NO: M2016286, aureus staphylophage J2-1P1 with the storage of CCTCC NO: M2016287, or aureus staphylophage J2-1P2 with the storage of CCTCC NO: M2016288. The phage is capable of preventing and treating human or animal bacterial infectious diseases caused by various staphylococcocci, particularly by aureus staphylophage; a good phage resource is provided to develop novel antimicrobial preparations; the novel staphylophage has a good application and development prospect.

The present invention discloses the new use of available antimalarial arteannuin and its derivatives dihydro arteannuin, antiannuic methyl ether, antiannuic ethyl ether and antiannuic amber. Arteannuin and its derivatives are used through combination with antibiotic medicine to inhibit bacterial growth and enhance the antibiotic effect of available antibiotic medicine. Especially, antiannuic amber is applied in preventing and treating bacterial infection diseases except being used as antimalarial.

The present invention relates to a lipid nanomaterial containing lysophosphatidylcholine or an ether derivative thereof, a method for preparing the same, a method for reducing erythrocyteolysis and hemagglutination using the compound, and a pharmaceutical agent containing the lipid nanomaterial. The present invention contains lysophosphatidylcholine or an ether derivative thereof as an active ingredient, and can be useful as a treatment agent for septicemia, bacterial infection diseases, and the like.

The invention relates a cyanopyridyl-replaced oxazolidinone compound with a general formula (I); wherein, R1 is hydrogen, fluorine, chlorine or trifluoromethyl and R is shown in the right structural formula. The invention also provides a preparation method of the compound shown in general formula (I) and medicinal salts of the compound and an application thereof for curing microbial infections, in particular to bacterial infection diseases. Preliminary antibacterial activity tests in vitro show that the compound of the invention has better antibacterial activity compared with linezolid and obvious antibacterial activity to drug-resistant bacteria.

The invention belongs to the field of medicines and particularly relates to a new application of an iridoid glycoside compound, genipin-1-[beta]-D-gentiobioside, and a composition composed by compounding the genipin-1-[beta]-Dgentiobioside with other components as effective components for preparing antiviral drugs, antibacterial drugs, fever alleviating drugs, inflammation resistant drugs and anti-oxidizing drugs. The iridoid glycoside compound and the composition can be used for treating acute respiratory infection, flu, pneumonia, viral hepatitis type B, herpes zoster, herpes viral keratitis, viral myocarditis, Epstein-Barr virus infection, retrovirus infectious diseases and bacterial infectious diseases.

The invention relates to cyclic nonapeptide amides and to methods for their preparation and to their use for the production of medicaments for the treatment and / or prophylaxis of diseases, especially bacterial infectious diseases.

The invention provides application of patchouli oil to preparing drugs for treating bacterial infectious diseases. The invention also provides a drug composition for treating the bacterial infectious diseases. The drug of the invention has stronger internal and external antibacterial activity on resistant strains in gram positive bacteria and gram negative bacteria and escherichia coli, can effectively treat infectious diseases caused by the resistant strains in clinical gram positive bacteria and gram negative bacteria as well as the resistant strains and sensitive strains in the escherichia coli, and provides a new drug selection for clinic.

The invention discloses an oil emulsion containing banksia rose oil and its preparing process, wherein the emulsion comprises rich costunolide and dehydrogenated costuslactone. The invention also provides its use in preparing medicament for the treatment of endotoxemia caused by various reasons.

Presented herein is a description for the manufacturing of inactivated HIV for use in vaccines against AIDS, as well as other inactivated viruses for other infectious diseases. This invention incorporates methods for inactivating infectious virus particles while retaining protein integrity and antigenicity. The methods utilize critical, near-critical or supercritical fluids with or without polar cosolvents. This invention would allow for the creation of HIV vaccines from genetically attenuated HIV strains for a greater degree of product safety, and from combinations of different HIV strains for broader protection. This HIV vaccine manufacturing technology is inexpensive, amenable to large-scale processing and portable, i.e. it can be readily implemented in a host country site. This invention can be utilized for other viral and bacterial infectious diseases, such as influenza and hepatitis.

The present invention discloses a combination of Chinese medicines for poultry and the preparation method and application. Hypericum forsythia and bidens grass are distilled. And then distilled liquid and residua are collected. The residua and the residual liquid after distillation being added with a hepatitis grass and a climbing nightshade are decocted three times. The decoction liquid is combined and concentrated to a thick concentration. A 95 percent ethanol is diluted to alcohol concentration of 60 percent to 70 percent. The drug liquid after sedimentation, filtration and concentration added with 95 percent ethanol are transferred to alcohol concentration of 75 percent to 80 percent and then are sedimentated and filtrated. The filtrate is concentrated. The drug liquid added with distilled water is frozenly precipitated, filtrated and concentrated. The combination of Chinese medicines is produced out after a combination of the distilled liquid of the hypericum forsythia and the bidens and the decoction liquid of the hepatitis grass and the climbing nightshade are combined. The combination of Chinese medicines has a cure rate of about 90% for a viruses and bacterial infectious disease of poultry, can be used to prepare the animal drug for treating duck viral hepatitis and chicken newcastle disease and has little side effect, safe use and fast absorption.

An objective of the present invention is to provide compounds of formula (I) or their pharmacologically acceptable salts or solvates wherein A represents aryl while R1 represents a five- or six-membered monocyclic heterocyclic group, or A represents a four- to six-membered monocyclic heterocyclic group while R1 represents aryl or a five- or six-membered monocyclic heterocyclic group; R2 represents a hydrogen atom or C1-6 alkyl; R3 represents C1-6 alkyl or C3-6 cycloalkyl-C1-4 alkyl; R4, R5, and R6 represent a hydrogen atom; R7 represents C1-6 alkyl; and m is 1 to 3. The compounds are novel lincosamide derivatives that have a potent activity against resistant Streptococcus pneumoniae. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

The invention provides application of tsaoko oil in preparation of a medicament for treating bacterial infection diseases. The invention provides a medicinal composition for treating bacterial infection diseases. The medicament has antibacterial activity on Gram positive bacteria and Gram negative bacteria, has strong bacteria inhibiting effect on medicament-resistant strains therein, has good antibacterial effect likewise in vivo, can effectively treat the infection diseases caused by various strains in clinical Gram positive bacteria and Gram negative bacteria, and provides a new medicament application selection for clinic.

This invention provides Cephem compounds having the formula:or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof, a pharmaceutical composition thereof, and a method for treating a bacterial infectious disease with the compound, the ester, the protected compound, the salt, or the solvate thereof, wherein the symbols in the formula are defined in the specification. The compounds exhibit potent antimicrobial spectrum against a variety of bacteria including Gram negative bacteria and / or Gram positive bacteria, preferably beta-lactamase producing Gram negative bacteria, more preferably, multi-drug resistant microbials, in particular, Class B type metallo-beta-lactamase producing Gram negative bacteria, and still preferably extended-spectrum beta-lactamase (ESBL) producing bacteria. The compounds most preferably do not exhibit cross-resistance against known Cephem drugs or Carbapenem drugs.

The present invention relates to a method for providing bactericide or bacteriostatic, especially for treating disease due to bacterial infection. The method comprising administering a patient in need of such treatment a therapeutically effective amount of a compound of dextromethorphan or naloxone or a pharmaceutically acceptable salt or an analog thereof. The compound is applied to skin or mucosal surface of the patient. The invention also relates to a method of treating inflammation caused by suppressing secretion of TNF-alpha, IL-6, or MCP-1 from macrophage comprising administering a patient in need of such treatment a therapeutically effective amount of NADPH oxidase inhibitor.

The invention belongs to the technical field of medicament, and particularly relates to a compound shown in formula (I) (please see the formula (I) in the description), and acceptable salt, ester or stereoisomer of the compound in pharmacy. R1, R2, a ring A and a ring B are defined in the description. The invention further relates to a preparation method, pharmaceutical preparations and pharmaceutical compositions of the compounds, and application of the compounds in preparation of medicines for treating and preventing bacterial infectious diseases.

The invention discloses a preparation method and application of a titanium alloy surface iodine-loaded antibacterial coating and belongs to the technical field of preparation of medical and biologicalmaterials. The preparation method comprises the following steps: deoiling, blasting sand and grinding, carrying out ultrasonic washing, washing with acid, washing with water, carrying out micro-arc anodic oxidation treatment, washing with water, carrying out electrophoresis, washing with water and sealing pores. A non-metallic material with an antibacterial effect is deposited in a porous bioactive film layer prepared on the surface of a titanium alloy; the risk of dissolving metal ions in the using process is avoided; the antibacterial coating is semi-closed; the explosive release of the iodine material of the antibacterial coating is prevented; the slow release time of the iodine material is obviously prolonged; a more efficient and lasting antibacterial effect can be achieved; the antibacterial sterilization rate of the in-vitro coating reaches 100%; the bonding strength between the antibacterial coating and a titanium alloy substrate is greater than 53MPa; the antibacterial effects of medical apparatus and instruments are ensured; the bacterial infectious diseases caused by the medical apparatus and instruments are reduced; and the inflammations of implants are reduced.

The invention relates to application of patchouli alcohol in preparing medicines treating bacteria infectious diseases and further provides a medicine composition treating the bacteria infectious diseases. The patchouli alcohol has excellent inhibitory activity to pathogenic bacteria or conditional pathogenic bacteria and can effectively treat the bacteria infectious diseases, meanwhile, the patchouli alcohol can also effectively resist methicillin-resistant staphylococcus epidermidi drug-resistance bacteria, the pharmacodynamics activity of the patchouli alcohol equals to vancomycin, and therefore probability is provided for slowing or avoiding occurring of the drug-resistance bacteria.

Bacterial resistance to antibiotics is increasing worldwide creating a global threat. Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is a bacterial infectious disease that results in over one million deaths annually. The discovery outlined here involves a tablet composition for patient administration and subsequently a new paradigm in drug delivery vehicles in vivo and in vitro and is applied to existing TB antibiotics in order to increase their efficacy. The drug delivery system is a three component complex that is administered with the TB antibiotic or a combination of TB antibiotics. The components are a saccharide or saccharides, a transition metal ion or a combination of metal ions that can bind a nitrogen and / or oxygen atom(s), and a water soluble polymer capable of aggregating and enclosing the other constituents. The three component molecular delivery approach has demonstrated ability to overcome M. tuberculosis bacterial resistance to an existing antibiotic.

The invention belongs to biological technique field, relates to small molecular inhibitor against staphylococci tryptophanyl-tRNA synthetase (WRS), molecular structure of the inhibitor shown in formula I, method of the inhibitor as medicament for preventive or treating relevant bacterial disease. Biochemical and biological experiments have shown that the inhibitor has strong binding force with target protein staphylococcus epidermidis or Staphylococcus aureus tryptophanyl-tRNA synthetase, can inhibit the activity of the synthetase, inhibit the growth of staphylococcus epidermidis Staphylococcus aureus. It has no toxicity to mammalian cell. The inventive inhibitor can be used for preparing medicament for treating disease caused by staphylococci, and preparing into disinfectant liquid.

The invention relates to a Chinese herbal medicine feed additive for controlling main bacterial infectious diseases of freshwater fish. The Chinese herbal medicine feed additive is prepared from the following raw materials in parts by weight: 3-5 parts of purslane, 3-4 parts of dahurian patrinia herb, 2-3 parts of erodium stephanianum willd, 1-2 parts of Chinese gall, 1-2 parts of rosa laevigata michx, 1-2 parts of garlic and 1-2 parts of liquorice. The Chinese herbal medicine feed additive for controlling the main bacterial infectious diseases of the freshwater fish is used for controlling the main bacterial infectious diseases of the freshwater fish, and has the characteristics of being high in cure rate, good in effect, safe, free from toxic and side effects and convenient to take.

The invention discloses an oxazolidinone compound with thiadiazole group as formula I and making method, wherein R 1 is H or F; m is integral between 1 and 4. The invention also provides the application to treat microbe, especially for bacteria infection disease.

An azithromycin derivative, its medicinal acceptable salt and its usage are disclosed. In structural formula of medicinal acceptable salt, IR is -R1 or -A-R1; A is C1-5 alkylene, C2-5 vinylene, C2-5 acetylene, C3-6 naphthelene, 3-6 valence heterocyclene or C6-10 arylene containing 1-2 selected from N, O and S hetero-atom; R1 is 5-15 valence aromatic nucleus containing 0-3 selected from N, O and S hetero-atom, which can be substituted by various substituting group. It can be used to prepare medicines in treatment and prevention of infectious diseases.

The invention relates to lysobactin amides and methods for their preparation, as well as their use for manufacturing medicaments for the treatment and / or prophylaxis of diseases, in particular bacterial infectious diseases.

The invention provides an application of patchoulenone or a derivative thereof in preparing medicines for treating bacterial infectious diseases. Furthermore, the invention provides a pharmaceutical composition for treating the bacterial infectious diseases. The patchoulenone has an excellent activity on inhibiting pathogenic bacteria such as staphylococcus and opportunistic pathogenic bacteria, and can effectively treat bacterial infectious diseases; and the patchoulenone can effectively inhibit methicillin-resistant drug-resistance bacteria, thus providing a new choice for clinical medication.